ESMO Congress October 2025: Poster Presentation on OSIBOOST 2A Trial

At the ESMO (European Society For Medical Oncology) Congress in October 2025 in Berlin, Paul Kruithof presented a poster on the OSIBOOST 2A trial. 
This study explores a potentially more cost effective treatment strategy for osimertinib, a drug used in the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. 

Although osimertinib is effective, its high cost remains a significant challenge. The Osiboost 2A trial explores the addition of cobicistat, a pharmacokinetic enhancer that inhibits the metabolism of osimertinib, also known as PK-boosting. This leads to increased plasma concentrations of osimertinib, potentially allowing for lower drug intake. OSIBOOST 2A is a feasibility study investigating whether a personalized strategy combining 'boosting' and reduced drug intake, can improve the affordability of treatment with osimertinib.
A published abstract of this trial is available via: https://doi.org/10.1016/j.annonc.2025.08.2602

Geef uw mening over de website, of vertel ons hoe wij onze website kunnen verbeteren.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.